Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Criterion validity of a computer-based tutorial for teaching waist circumference self-measurement.

Elliott WL.

J Bodyw Mov Ther. 2008 Apr;12(2):133-45. doi: 10.1016/j.jbmt.2007.10.007. Epub 2007 Dec 26.

PMID:
19083665
2.

Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA, Roberts BJ, Fry DW, Gonzales AJ, Harvey PJ, Nelson JM, Sherwood V, Han HK, Pace G, Smaill JB, Denny WA, Showalter HD.

J Med Chem. 2006 Feb 23;49(4):1475-85.

PMID:
16480284
3.

Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor.

Christensen JG, Vincent PW, Klohs WD, Fry DW, Leopold WR, Elliott WL.

Mol Cancer Ther. 2005 Jun;4(6):938-47.

4.

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J 3rd, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL.

J Med Chem. 2005 Apr 7;48(7):2371-87.

PMID:
15801830
5.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL.

Mol Cancer Ther. 2004 Nov;3(11):1427-38.

6.

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.

Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW.

Semin Oncol. 2002 Jun;29(3 Suppl 11):11-21. Review.

PMID:
12138393
7.

CI-1033, a pan-erbB tyrosine kinase inhibitor.

Slichenmyer WJ, Elliott WL, Fry DW.

Semin Oncol. 2001 Oct;28(5 Suppl 16):80-5. Review.

PMID:
11706399
8.

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.

Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, Fry DW, Nelson JM, Sherwood V, Vincent PW, Roberts BJ, Elliott WL, Denny WA.

J Med Chem. 2001 Feb 1;44(3):429-40.

PMID:
11462982
9.

Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.

Schroeder MC, Hamby JM, Connolly CJ, Grohar PJ, Winters RT, Barvian MR, Moore CW, Boushelle SL, Crean SM, Kraker AJ, Driscoll DL, Vincent PW, Elliott WL, Lu GH, Batley BL, Dahring TK, Major TC, Panek RL, Doherty AM, Showalter HD.

J Med Chem. 2001 Jun 7;44(12):1915-26.

PMID:
11384237
10.

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.

Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Showalter HD, Vincent PW, Elliott WL, Denny WA.

J Med Chem. 2000 Apr 6;43(7):1380-97.

PMID:
10753475
11.

3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.

Thompson AM, Connolly CJ, Hamby JM, Boushelle S, Hartl BG, Amar AM, Kraker AJ, Driscoll DL, Steinkampf RW, Patmore SJ, Vincent PW, Roberts BJ, Elliott WL, Klohs W, Leopold WR, Showalter HD, Denny WA.

J Med Chem. 2000 Nov 2;43(22):4200-11.

PMID:
11063616
12.

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido

Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Showalter HD, Vincent PW, Elliott WL, Denny WA.

J Med Chem. 2000 Aug 10;43(16):3199. No abstract available.

PMID:
10956451
13.

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.

Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H, Elliott WL.

Cancer Chemother Pharmacol. 2000;45(3):231-8.

PMID:
10663641
14.

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.

Boschelli DH, Wu Z, Klutchko SR, Showalter HD, Hamby JM, Lu GH, Major TC, Dahring TK, Batley B, Panek RL, Keiser J, Hartl BG, Kraker AJ, Klohs WD, Roberts BJ, Patmore S, Elliott WL, Steinkampf R, Bradford LA, Hallak H, Doherty AM.

J Med Chem. 1998 Oct 22;41(22):4365-77.

PMID:
9784112
15.

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM.

J Med Chem. 1998 Aug 13;41(17):3276-92.

PMID:
9703473
17.
18.

Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.

Showalter HD, Sercel AD, Leja BM, Wolfangel CD, Ambroso LA, Elliott WL, Fry DW, Kraker AJ, Howard CT, Lu GH, Moore CW, Nelson JM, Roberts BJ, Vincent PW, Denny WA, Thompson AM.

J Med Chem. 1997 Feb 14;40(4):413-26.

PMID:
9046331
19.

Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.

Kunkel MW, Hook KE, Howard CT, Przybranowski S, Roberts BJ, Elliott WL, Leopold WR.

Invest New Drugs. 1996;13(4):295-302.

PMID:
8824347
22.

Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity.

Fry DW, Kraker AJ, Connors RC, Elliott WL, Nelson JM, Showalter HD, Leopold WR.

Anticancer Drug Des. 1994 Aug;9(4):331-51.

PMID:
7916900
23.

Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.

Kraker AJ, Hoeschele JD, Elliott WL, Showalter HD, Sercel AD, Farrell NP.

J Med Chem. 1992 Nov 27;35(24):4526-32.

PMID:
1335074
24.

Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.

Sebolt-Leopold JS, Vincent PW, Beningo KA, Elliott WL, Leopold WR, Heffner TG, Wiley JN, Stier MA, Suto MJ.

Int J Radiat Oncol Biol Phys. 1992;22(3):549-51.

PMID:
1531213
25.

In vivo and in vitro evaluation of the alkylating agent carmethizole.

Elliott WL, Fry DW, Anderson WK, Nelson JM, Hook KE, Hawkins PA, Leopold WR 3rd.

Cancer Res. 1991 Sep 1;51(17):4581-7.

26.

Preclinical antitumor activity of CI-973,[SP-4-3-(R)]-[1,1- cyclobutanedicarboxylato(2-)](2 methyl-1,4-butane-diamine-N,N')platinum.

Kraker AJ, Moore CW, Roberts BJ, Leopold WR, Elliott WL.

Invest New Drugs. 1991 Feb;9(1):1-7.

PMID:
2026477
27.

Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.

Waud WR, Leopold WR, Elliott WL, Dykes DJ, Laster WR Jr, Temple CG Jr, Harrison SD Jr, Griswold DP Jr.

Cancer Res. 1990 Jun 1;50(11):3239-44.

28.

Oncolytic activity and mechanism of action of a novel L-cysteine derivative, L-cysteine, ethyl ester, S-(N-methylcarbamate) monohydrochloride.

Jayaram HN, Lui MS, Plowman J, Pillwein K, Reardon MA, Elliott WL, Weber G.

Cancer Chemother Pharmacol. 1990;26(2):88-92.

PMID:
2347042
29.

Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice.

Elliott WL, Howard CT, Dykes DJ, Leopold WR.

Cancer Res. 1989 Oct 15;49(20):5586-90.

30.
31.

Proteolytic cleavage of Ii to p25.

Thomas LJ, Nguyen QV, Elliott WL, Humphreys RE.

J Immunol. 1988 Apr 15;140(8):2670-4.

PMID:
3282009
32.

Insulin regulatory effects on purine- and pyrimidine metabolism in alloxan diabetic rat liver.

Pillwein K, Reardon MA, Jayaram HN, Natsumeda Y, Elliott WL, Faderan MA, Prajda N, Sperl W, Weber G.

Padiatr Padol. 1988;23(2):135-44.

PMID:
3043317
33.
34.

An hypothesis on the binding of an amphipathic, alpha helical sequence in Ii to the desetope of class II antigens.

Elliott WL, Stille CJ, Thomas LJ, Humphreys RE.

J Immunol. 1987 May 1;138(9):2949-52.

PMID:
3494776
35.

Hyperexpressed hairy leukemic cell Ii might bind to the antigen-presenting site of class II MHC molecules.

Elliott WL, Lu S, Nguyen Q, Reisert PS, Sairenji T, Sorli CH, Stille CJ, Thomas LJ, Humphreys RE.

Leukemia. 1987 Apr;1(4):395-6.

PMID:
2823017
36.

In vivo inactivation of formylglycinamidine ribonucleotide synthetase in rat hepatoma.

Elliott WL, Weber G.

Biochem Pharmacol. 1985 Jan 15;34(2):243-8.

PMID:
3966925
37.

Decreased NADH-oxidoreductase activities as an early response in rat liver to the carcinogen 2-acetylaminofluorene.

Sun I, MacKellar WC, Crane FL, Barr R, Elliott WL, Lem N, Varnold RL, Heinstein PF, Morré DJ.

Cancer Res. 1985 Jan;45(1):157-63.

38.

Cyclic modulation of enzymes of pyrimidine nucleotide biosynthesis precedes sialoglycoconjugate changes during 2-acetylaminofluorene-induced hepatocarcinogenesis in the rat.

Elliott WL, Sawick DP, DeFrees SA, Heinstein PF, Cassady JM, Morré DJ.

Biochim Biophys Acta. 1984 Jul 30;800(2):194-201.

PMID:
6331524
39.
40.

Sialoglycoconjugate changes during 2-acetylaminofluorene-induced hepatocarcinogenesis in the rat.

Creek KE, Walter VP, Evers D, Yeo E, Elliott WL, Heinstein PF, Morré DM, Morré DJ.

Biochim Biophys Acta. 1984 Apr 18;793(2):133-40.

PMID:
6712962
41.

Control of enzymic programs and nucleotide pattern in cancer cells by acivicin and tiazofurin.

Weber G, Natsumeda Y, Lui MS, Faderan MA, Liepnieks JJ, Elliott WL.

Adv Enzyme Regul. 1984;22:69-93.

PMID:
6206692
42.

Early biochemical alterations induced by 2-acetylaminofluorene in rat liver.

Elliott WL, Sawick DP, Creek KE, Deutscher SL, Quinn JF, Yeo E, Webb WR, Morré DM, Harrington DD, Heinstein PF, et al.

Int J Biochem. 1984;16(9):947-56.

PMID:
6148271
43.

Changes in protein kinase activities during 2-acetylaminofluorene-induced hepatocarcinogenesis in the rat.

Schiller-Smith SL, Varnold RL, Morré DJ, Elliott WL, Heinstein PF.

Int J Biochem. 1983;15(8):997-1002.

PMID:
6311638

Supplemental Content

Loading ...
Support Center